SCHEMBL222332

SCHEMBL222332

O=C1Cc2cc(F)c(Cl)cc2N1

nearest known ligand 0.53

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
AHR P35869 5/20 0.53
CMA1 P23946 2/20 0.53
TDP2 O95551 1/20 0.48
PGR P06401 1/20 0.44
SMYD3 Q9H7B4 2/20 0.44
EIF2AK2 P19525 1/20 0.43
PDK2 Q15119 1/20 0.41
GRIA1 P42261 2/20 0.41
CACNG8 Q8WXS5 2/20 0.41
MAOB P27338 2/20 0.40
PDE3B Q13370 1/20 0.40
PDE3A Q14432 1/20 0.40
PKM P14618 1/20 0.39
KIF11 P52732 1/20 0.39
GAA P10253 1/20 0.39
BCL6 P41182 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5441646 0.84 AHR (0.60) AHRCMA1PGRSMYD3EIF2AK2
SCHEMBL548762 0.84 AHR (0.50) AHRCMA1TDP2PGREIF2AK2
SCHEMBL30888599 0.84 PKM (0.53) PKMKIF11
SCHEMBL4779437 0.84 PKM (0.53) PKMKIF11
SCHEMBL1847559 0.78 AHR (0.53) AHRCMA1TDP2PGREIF2AK2
SCHEMBL16050307 0.78 AHR (0.53) AHRCMA1TDP2PGRSMYD3
SCHEMBL11106607 0.78 AHR (0.53) AHRCMA1PGRSMYD3EIF2AK2
SCHEMBL17120924 0.78 AHR (0.53) AHRCMA1PGRSMYD3EIF2AK2
SCHEMBL31727396 0.78 HDAC3 (0.46) AHRCMA1TDP2PGRSMYD3
SCHEMBL29004729 0.78 AHR (0.53) AHRCMA1TDP2PGRSMYD3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 101 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12545685-B2 Dispiropyrrolidine derivatives DAIICHI SANKYO COMPANY, LIMITED (JP) 2026-02-10 US disclosed
CN-115836064-B Triazine derivative with EGFR (epidermal growth factor receptor) inhibition activity as well as preparation method and application thereof 上海和誉生物医药科技有限公司 2024-08-27 CN disclosed
US-20240246989-A1 DISPIROPYRROLIDINE DERIVATIVES DAIICHI SANKYO COMPANY, LIMITED (JP) 2024-07-25 US disclosed
US-20240150287-A1 N-(BENZOYL)-PHENYLALANINE COMPOUND, PHARMACEUTICAL COMPOSITION CONTAINING SAME, AND USE THEREOF HANGZHOU APELOA MEDICINE RESEARCH INSTITUTE CO., LTD. (CN) 2024-05-09 US disclosed
EP-4282865-A1 N-(BENZOYL)-PHENYLALANINE COMPOUND, PHARMACEUTICAL COMPOSITION CONTAINING SAME, AND USE THEREOF Hangzhou Apeloa Medicine Research Institute Co., Ltd. (CN) 2023-11-29 EP disclosed
CN-116997550-A N- (benzoyl) -phenylalanine compounds, pharmaceutical compositions containing same and application thereof 杭州普洛药物研究院有限公司 2023-11-03 CN disclosed
CN-115836064-A Triazine derivative with EGFR (epidermal growth factor receptor) inhibitory activity and preparation method and application thereof 上海和誉生物医药科技有限公司 2023-03-21 CN disclosed
CN-114853659-A N- (benzoyl) -phenylalanine compounds, pharmaceutical compositions containing same, and uses thereof 普洛药业股份有限公司 2022-08-05 CN disclosed
US-20220106324-A1 DISPIROPYRROLIDINE DERIVATIVES DAIICHI SANKYO COMPANY, LIMITED (JP) 2022-04-07 US disclosed
US-20220106324-A1 DISPIROPYRROLIDINE DERIVATIVES DAIICHI SANKYO COMPANY, LIMITED (JP) 2022-04-07 US disclosed
US-4690943-A ENZYME INHIBITOR OF CYCLOOXYGENASE AND LIPOXYGENASE PFIZER INC. (US) 1987-09-01 US disclosed
US-4658037-A RHEUMATIC DISEASES PFIZER INC. (US) 1987-04-14 US disclosed
CN-85103527-A Preparation N, the method for the disubstituted 2-hydroxyindole of 3--1-hydroxyalkyl cooh amide 1987-01-28 CN disclosed
EP-0208510-A2 1-Substituted oxindole-3-carboxamines as antiinflammatory and analgesic agents PFIZER INC. (US) 1987-01-14 EP disclosed
EP-0175551-A1 Analgesic and antiinflammatory 1,3-diacyl-2-oxindole compounds PFIZER INC. (US) 1986-03-26 EP disclosed
US-4569942-A N,3-Disubstituted 2-oxindole-1-carboxamides as analgesic and antiinflammatory agents PFIZER INC. (US) 1986-02-11 US disclosed
EP-0164860-A1 N,3-disubstituted 2-oxindole-1-carboxamides as analgesic and antiinflammatory agents PFIZER INC. (US) 1985-12-18 EP disclosed
US-4556672-A 3-Substituted 2-oxindole-1-carboxamides as analgesic and anti-inflammatory agents PFIZER INC. (US) 1985-12-03 US disclosed
EP-0156603-A2 3-Substituted 2-oxindole-1-carboxamides as analgesic and anti-inflammatory agents PFIZER INC. (US) 1985-10-02 EP disclosed
EP-0153818-A2 1,3-Disubstituted 2-oxindoles as analgesic and anti-inflammatory agents PFIZER INC. (US) 1985-09-04 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240150287-A1 N-(BENZOYL)-PHENYLALANINE COMPOUND, PHARMACEUTICAL COMPOSITION CONTAINING SAME, AND USE THEREOF ITGB7, ITGB4, ITGA4 AHR 1172/4885CMA1 1058/4885TDP2 3861/4885
US-12545685-B2 Dispiropyrrolidine derivatives TP53, MDM2, TP53BP1 AHR 3275/4885CMA1 3900/4885TDP2 1958/4885
US-20240246989-A1 DISPIROPYRROLIDINE DERIVATIVES MDM2, TP53, TP53BP1 AHR 2432/4885CMA1 2799/4885TDP2 1672/4885
US-20220106324-A1 DISPIROPYRROLIDINE DERIVATIVES MDM2, TP53, TP53BP1 AHR 2432/4885CMA1 2799/4885TDP2 1672/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.